Krabbe´s disease: case report on the phenotypic spectrum of a multifaceted metabolic leukodystrophy
DOI:
https://doi.org/10.17696/2318-3691.28.1.2021.1808Keywords:
Leukodystrophy, Globoid Cell; Galactosylceramidase; Leukodystrophy, Globoid Cell, Neonatal Screening; PsychosineAbstract
Introduction: Krabbe's disease, also known as globoid cell leukodystrophy, is a rare autosomal recessive disorder caused by galactocerebrosidase (GALC) deficiency. Its diagnosis is based on an enzymatic test followed by molecular genetic study of the GALC gene. Clinical manifestations are diverse and include motor alterations, cognitive involvement with irritability, spasticity and developmental regression, with death at a very early age in the classic infantile form. In late-onset forms, the phenotypes are more attenuated with gait abnormalities and slower progression. Objectives: To demonstrate the phenotypic variability of a Brazilian cohort considering the multiethnic character of this population, and to emphasize=point out the importance of early diagnosis for the possibility of treatment, since there is evidence of improvement in evolution and prognosis. Case Study: Three cases of male patients with Globoid Cell Leukodystrophy are presented, all children of non-consanguineous parents, with molecular diagnosis and without common variation, reinforcing the multiethnic character of the Brazilian population. The onset age of clinical manifestations varied (one month, eight months and two years) and the disease was diagnosed between three months and wo years of age. The patients had neuropsychomotor development delay, different neurological manifestations and brain magnetic resonance imaging was similar between them. The study patients did not receive treatment because they were not diagnosed early and two of them had complications of the disease and died. Conclusion: Globoid Cell Leukodystrophy presents a high phenotypic variability with multiple manifestations. Furthermore, the early diagnosis of the disease is a challenge that directly impacts the prognosis and the only therapy currently available; bone marrow transplantation. Additionally, the accurate diagnosis of the disease enables family genetic counseling and helps to improve the patient's rehabilitation care.
References
Gucev Z, Tasic V. Compound Galactosylceramidase Gene (GALC) Heterozygosity in a Boy with Infantile Krabbe Disease (KD). Prilozi. 2015;36(3):99-101. doi: 10.1515/prilozi-2015-0084
Sano TS. Doença de Krabbe: a importância do diagnóstico precoce para seu prognóstico. EINSTEIN. 2012;10(2):233-5. doi: 10.1590/S1679-45082012000200019
Beltran-Quintero ML, Bascou NA, Poe MD, Wenger DA, Saavedra-Matiz CA, Nichols MJ, et al. Early progression of Krabbe disease in patients with symptom onset between 0 and 5 months. Orphanet J Rare Dis. 2019;14(1):46. doi: 10.1186/s13023-019-1018-4
Kohlschütter A. Lysosomal leukodystrophies: Krabbe disease and metachromatic leukodystrophy. Handb Clin Neurol. 2013;113:1611-8. doi: 10.1016/B978-0-444-59565-2.00029-0
Bascou N, DeRenzo A, Poe MD, Escolar ML. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. Orphanet J Rare Dis. 2018;13(1):126. doi: 10.1186/s13023-018-0872-9
Adachi H, Ishihara K, Tachibana H, Oka N, Higuchi Y, Takashima H, et al. Adult-onset Krabbe disease presenting with an isolated form of peripheral neuropathy. Muscle Nerve. 2016;54(1):152-7. doi: 10.1002/mus.25067
Orsini JJ, Kay DM, Saavedra-Matiz CA, Wenger DA, Duffner PK, Erbe RW, et al . Newborn screening for Krabbe disease in New York State: the first eight years’ experience. Genet Med. 2016;18(3):239-48. doi: 10.1038/gim.2015.211
Wenger DA, Luzi P. Chapter 30 - Krabbe disease: Globoid Cell Leukodystrophy [Internet]. In: Rosenberg RN, Pascual JM, organizadores. Rosenberg’s molecular and genetic basis of neurological and psychiatric disease (Fifth Edition). Boston: Academic Press; 2015 [acesso em 2018 Out 2]. Disponível em: https://doi.org/10.1016/B978-0-12-410529-4.00030-9
Duffner PK, Barczykowski A, Kay DM, Jalal K, Yan L, Abdelhalim A, et al. Later onset phenotypes of Krabbe disease: results of the world-wide registry. Pediatr Neurol. 2012;46(5):298-306. doi: 10.1016/j.pediatrneurol.2012.02.023
Poretti A, Blaser SI, Lequin MH, Fatemi A, Meoded A, Northington FJ, et al. Neonatal neuroimaging findings in inborn errors of metabolism. J Magn Reson Imaging. 2013;37(2):294-312. doi: 10.1002/jmri.23693.
Orsini JJ, Escolar ML, Wasserstein MP, Caggana M. Krabbe Disease. 2000 Jun 19 [Updated 2018 Oct 11] [homepage na Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019 [acesso em 2018 out 2]. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK1238/)
Pannuzzo G, Graziano ACE, Avola R, Drago F, Cardile V. Screening for Krabbe disease: the first 2 years’ experience. Acta Neurol Scand. 2019;140(5):359-65. doi: 10.1111/ane.13153
Hult M, Darin N, Von Döbeln U, Månsson JE. Epidemiology of lysosomal storage diseases in Sweden. Acta Paediatr. 2014;103(12):1258-63. doi: 10.1111/apa.12807
Zlotogora J, Regev R, Zeigler M, Iancu TC, Bach G. Krabbe disease: in- creased incidence in a highly inbred community. Am J Med Genet. 1985;21(4):765-70. doi: 10.1002/ajmg.1320210420
Orsini JJ, Saavedra-Matiz CA, Gelb MH, Caggana M. Newborn Screening for Krabbe’s Disease. J Neurosci Res. 2016;94(11):1063-75. doi:10.1002/jnr.23781 16. Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018;13(1):30. doi: 10.1186/s13023-018-0766-x
Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018;13(1):30. doi: 10.1186/s13023-018-0766-x
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.